Immunomedics (IMMU) 10-Q 5 Nov 14 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Sep. 30, 2014	Nov. 04, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2015	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'IMMU	'
Entity Registrant Name	'IMMUNOMEDICS INC	'
Entity Central Index Key	'0000722830	'
Current Fiscal Year End Date	'--06-30	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	93,133,094

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Jun. 30, 2014
ASSETS	'	'
Cash and cash equivalents	$5,445,475	$6,961,494
Marketable securities	26,541,857	34,871,120
Accounts receivable, net of allowance for doubtful accounts of $86,537 at September 30, 2014 and $88,609 at June 30, 2014	555,474	674,617
Inventory	732,409	778,989
Other receivables	300,647	303,102
Prepaid expenses	1,842,922	1,614,897
Other current assets	104,603	180,678
Total current assets	35,523,387	45,384,897
Property and equipment, net of accumulated depreciation of $27,453,741 and $27,312,924 at September 30, 2014 and June 30, 2014, respectively	2,086,408	1,895,475
Value of life insurance policies	176,110	176,110
Other long-term assets	30,000	30,000
Total Assets	37,815,905	47,486,482
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'
Accounts payable and accrued expenses	9,338,884	6,886,682
Deferred revenues	243,305	240,158
Total current liabilities	9,582,189	7,126,840
Other liabilities	1,525,123	1,500,244
Commitments and Contingencies	'	'
Stockholders' Equity:	'	'
Preferred stock, $0.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at September 30, 2014 and June 30, 2014	'	'
Common stock, $0.01 par value; authorized 135,000,000 shares; issued 93,157,819 shares and outstanding 93,123,094 shares at September 30, 2014; and issued 93,113,480 shares and outstanding 93,078,755 shares at June 30, 2014	931,577	931,134
Capital contributed in excess of par	300,554,900	300,080,804
Treasury stock, at cost, 34,725 shares at September 30, 2014 and at June 30, 2014	-458,370	-458,370
Accumulated deficit	-273,876,058	-261,465,638
Accumulated other comprehensive income	79,255	261,837
Total Immunomedics, Inc. stockholders' equity	27,231,304	39,349,767
Noncontrolling interest in subsidiary	-522,711	-490,369
Total stockholders' equity	26,708,593	38,859,398
Total Liabilities and Stockholders' Equity	$37,815,905	$47,486,482

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Jun. 30, 2014
Statement of Financial Position [Abstract]	'	'
Accounts receivable, allowance for doubtful accounts	$86,537	$88,609
Property and equipment, accumulated depreciation	$27,453,741	$27,312,924
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	135,000,000	135,000,000
Common stock, shares issued	93,157,819	93,113,480
Common stock, shares outstanding	93,123,094	93,078,755
Treasury stock, shares	34,725	34,725

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Revenues:	'	'
Product sales	$727,633	$559,023
License fee and other revenues	'	4,623,333
Research and development	344,365	315,465
Total revenues	1,071,998	5,497,821
Costs and Expenses:	'	'
Costs of goods sold	76,286	77,199
Cost of license fee and other revenues	'	1,189,170
Research and development	9,392,017	7,514,094
Sales and marketing	228,637	218,032
General and administrative	3,819,192	1,732,671
Total costs and expenses	13,516,132	10,731,166
Operating loss	-12,444,134	-5,233,345
Interest and other income, net	25,072	6,211
Foreign currency transaction (loss) gain	-11,737	5,452
Loss before income tax expense	-12,430,799	-5,221,682
Income tax expense	-11,963	-4,501
Net loss	-12,442,762	-5,226,183
Less: Net loss attributable to noncontrolling interest	-32,342	-25,220
Net loss attributable to Immunomedics, Inc. stockholders	-12,410,420	-5,200,963
Loss per common share attributable to Immunomedics, Inc. stockholders, (basic and diluted)	($0.13)	($0.06)
Weighted average shares used to calculate loss per common share, (basic and diluted)	93,098,202	82,947,124
Other comprehensive (loss) income, net of tax:	'	'
Foreign currency translation adjustments	-178,130	72,367
Unrealized losses on available-for-sale securities	-4,452	-4,960
Other comprehensive (loss) income	-182,582	67,407
Comprehensive loss	-12,625,344	-5,158,776
Less comprehensive loss attributed to noncontrolling interest	-32,342	-25,220
Net comprehensive loss attributable to Immunomedics, Inc.	($12,593,002)	($5,133,556)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows used in operating activities:	'	'
Net loss	($12,442,762)	($5,226,183)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	140,817	157,188
Amortization of deferred revenue	3,147	-2,515,766
(Decrease) increase in allowance for doubtful accounts	-2,072	21,153
Non-cash expense related to stock compensation	561,110	418,548
Gain from the sales of marketable securities	-7,215	'
Non-cash increase in value of life insurance policy	'	-4,250
Amortization of deferred rent	24,879	24,879
Changes in other operating assets and liabilities	2,475,308	-139,274
Net cash used in operating activities	-9,246,788	-7,263,705
Cash flows provided by (used in) investing activities:	'	'
Proceeds from sales/maturities of marketable securities	8,336,478	'
Purchase of marketable securities	'	-20,082,913
Purchases of property and equipment	-331,750	-144,764
Net cash provided by (used in) investing activities	8,004,728	-20,227,677
Cash flows (used in) provided by financing activities:	'	'
Tax withholding payments for stock compensation	-86,571	-159,436
Exercise of stock options, net	'	910,677
Net cash (used in) provided by financing activities	-86,571	751,241
Effect of changes in exchange rates on cash and cash equivalents	-187,388	57,191
Net decrease in cash and cash equivalents	-1,516,019	-26,682,950
Cash and cash equivalents, beginning of period	6,961,494	41,326,000
Cash and cash equivalents, end of period	$5,445,475	$14,643,050

Business_Overview_and_Basis_of

Business Overview and Basis of Presentation	3 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Business Overview and Basis of Presentation	'
	1	Business Overview and Basis of Presentation
	Immunomedics is a clinical-stage biopharmaceutical company that develops monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. The Company has continued to transition its focus away from the development and commercialization of diagnostic imaging products in order to accelerate the development of its therapeutic product candidates, although the Company still manufactures and commercializes its LeukoScan® product in territories where regulatory approvals have previously been granted in Europe, Canada and in other markets outside the U.S. LeukoScan® is indicated for diagnostic imaging for determining the location and extent of infection and inflammation in bone of patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The Company has two foreign subsidiaries, Immunomedics B.V. in The Netherlands and Immunomedics GmbH in Darmstadt, Germany, that assist the Company in managing sales efforts and coordinating clinical trials in Europe. In addition, included in the accompanying condensed financial statements is the majority-owned U.S. subsidiary, IBC Pharmaceuticals, Inc. (“IBC”), which works on the development of novel cancer radiotherapeutics using patented pre-targeting technologies with proprietary, bispecific antibodies.
	The accompanying unaudited condensed consolidated financial statements of Immunomedics, which incorporate our subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Regulation S-X. Accordingly, the statements do not include all of the information and footnotes required by GAAP for complete annual financial statements. With respect to the financial information for the interim periods included in this Quarterly Report on Form 10-Q, which is unaudited, management believes that all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of the results for such interim periods have been included. Operating results for the three-month period ended September 30, 2014 are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2015, or any other period.
	Immunomedics is subject to significant risks and uncertainties, including, without limitation, the risk that the Company may be unable to successfully obtain financing for product development; the Company’s inability to further identify, develop and achieve commercial success for new products and technologies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that the Company may be unable to secure regulatory approval of and market its drug candidates; the Company’s dependence upon pharmaceutical and biotechnology collaborations; the levels and timing of payments under the Company’s collaborative agreements, if any; uncertainties about the Company’s ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development or regulatory approval of competing products; the Company’s ability to protect its proprietary technologies; patent-infringement claims; and risks of new, changing and competitive technologies and regulations in the United States and internationally.
	Since its inception in 1982, Immunomedics’ principal sources of funds have been the private and public sale of equity and debt securities and revenues from licensing agreements, which could provide up-front and milestone payments, as well as funding of development costs and other licensing possibilities. The Company’s ability to raise capital through public and private debt or equity financings may be negatively impacted by the economy. There can be no assurances that financings will be available when needed with acceptable terms to it, if at all. If the Company were unable to raise capital on acceptable terms, its ability to continue its business would be materially and adversely affected. Furthermore, the terms of any such debt or equity financing may include covenants which may limit the Company’s future ability to manage the business. At the present time, the Company is unable to determine whether any of these future activities will be successful and, if so, the terms and timing of any definitive agreements.
	The Company’s budgeted cash requirements in fiscal year 2015 are expected to be approximately $41.0 million, which includes expenses related to the clivatuzumab tetraxetan Phase 3 clinical trial for the treatment of patients with pancreatic cancer, as well as for expenses for the ongoing Phase 2 expansion ADC clinical trials (IMMU-132 and IMMU 130). The Company has the ability to reduce its cash flow spending requirements if necessary, after considering certain planned discretionary spending, including the funding of the Company’s clinical trial programs. For the three-month period ended September 30, 2014, the Company utilized cash aggregating $9.8 million. As of September 30, 2014, the Company has $32.0 million of cash, cash equivalents and marketable securities. The Company will require additional funding in order to fund its planned Phase 3 and Phase 2 clinical trials in fiscal 2015 and beyond.
	The Company continues to pursue business development and licensing arrangements as a potential source of financing. These activities include potential payments from partners, UCB S.A. (“UCB”) and The Bayer Group (“Bayer”), as well as any new parties who may be interested in clinical programs as well as any licenses to the Company’s vast intellectual property estate. State and Federal Grants, along with potential debt and equity financing may also be other sources of financing.
	The Company expects research and development activities to continue to expand over time, and it does not believe it will have adequate cash to continue to complete development of product candidates in line with its pipeline included in its long term corporate strategy. As a result, the Company will continue to require additional financial resources in order to conduct its research and development programs, clinical trials of product candidates and regulatory filings.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2	Summary of Significant Accounting Policies
	These unaudited condensed consolidated interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2014. The Company adheres to the same accounting policies in preparation of its interim financial statements.
	Principles of Consolidation and Presentation
	The condensed consolidated financial statements include the accounts of Immunomedics and its subsidiaries. Noncontrolling interests in consolidated subsidiaries in the condensed consolidated balance sheets represent minority stockholders’ proportionate share of the equity (deficit) in such subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
	Financial Instruments
	The carrying amounts of cash and cash equivalents, other current assets and current liabilities approximate fair value due to the short-term maturity of these instruments. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.
	Estimated Fair Value of Financial Instruments
	The Company has categorized its financial assets, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. The Company does not have any financial liabilities that are required to be measured at fair value on a recurring basis. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
	Financial assets recorded on the condensed consolidated balance sheets as of September 30, 2014 and June 30, 2014 are categorized based on the inputs to the valuation techniques as follows (in thousands):
		•		Level 1 – Financial assets whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the company has the ability to access at the measurement date (examples include active exchange-traded equity securities and most U.S. Government and agency securities).
		•		Level 2 – Financial assets whose value are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.
		•		Level 3 – Financial assets whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset.
			($ in thousands)
	September 30, 2014		Level 1			Level 2		Level 3		Total
	Money Market Funds		$	1,264		$	—	$	—	$	1,264
	Marketable Securities:
	U.S. Treasury Bonds			5,530			—		—		5,530
	U.S. Government Sponsored Agencies			7,453			—		—		7,453
	Corporate Debt Securities			13,559			—		—		13,559
	Total		$	27,806		$	—	$	—	$	27,806
			($ in thousands)
	June 30, 2014		Level 1			Level 2		Level 3		Total
	Money Market Funds		$	367		$	—	$	—	$	367
	Marketable Securities:
	U.S. Treasury Bonds			8,537			—		—		8,537
	U.S. Government Sponsored Agencies			7,457			—		—		7,457
	Corporate Debt Securities			18,877			—		—		18,877
	Total		$	35,238		$	—	$	—	$	35,238
	The money market funds noted above are included in cash and cash equivalents.
	Marketable Securities
	Marketable securities, all of which are available-for-sale, consist of corporate debt securities and municipal bonds. Marketable securities are carried at fair value, with unrealized gains and losses, net of related income taxes, reported as accumulated other comprehensive income, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses, and declines in value judged to be other-than-temporary on available-for-sale securities are included in the determination of net (loss) income and are included in interest and other income (net), at which time the average cost basis of these securities are adjusted to fair value. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included interest and other income (net).
	Inventory
	Inventory, which consists only of the finished product of LeukoScan®, is stated at the lower of cost (which approximates first-in, first-out) or market, and includes materials, labor and manufacturing overhead.
	Revenue Recognition
	The Company has accounted for revenue arrangements that include multiple deliverables as a separate unit of accounting if both of the following criteria are met: a) the delivered item has value to the customer on a standalone basis, and b) if the right of return exists, delivery of the undelivered items is considered probable and substantially in the control of the vendor. If these criteria are not met, the revenue elements must be considered a single unit of accounting for purposes of revenue recognition. The Company allocates revenue consideration, excluding contingent consideration, based on the relative selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Relative selling prices are determined using vendor specific objective evidence, if it exists; otherwise third-party evidence or the Company’s best estimate of selling price is used for each deliverable.
	Payments received under contracts to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Payments received in advance that are related to future performance are deferred and recognized as revenue when the research projects are performed. Upfront nonrefundable fees associated with license and development agreements where the Company has continuing involvement in the agreement are recorded as deferred revenue and recognized over the estimated service period. The Company estimates the period of continuing involvement based on the best evidential matter available at each reporting period. If the estimated service period is subsequently modified, the period over which the upfront fee is recognized is modified accordingly on a prospective basis.
	In order to determine the revenue recognition for contingent milestones, the Company evaluates the contingent milestones using the criteria as provided by the Financial Accounting Standards Boards (“FASB”) guidance on the milestone method of revenue recognition, as explained in ASU 2010-17, “Milestone Method of Revenue Recognition”, at the inception of a collaboration agreement. The criteria requires that (i) the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from the Company’s activities to achieve the milestone, (ii) the milestone be related to past performance, and (iii) the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved. Royalties are recognized as earned in accordance with the terms of various research and collaboration agreements.
	Revenue from the sale of diagnostic products is recorded when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed and determinable or collectability is reasonably assured. Allowances, if any, are established for uncollectible amounts, estimated product returns and discounts. Since allowances are recorded based on management’s estimates, actual amounts may be different in the future.
	Research and Development Costs
	Research and development costs are expensed as incurred. Costs incurred for clinical trials for patients and investigators are expensed as services are performed in accordance with the agreements in place with their clinical sites.
	Reimbursement of Research & Development Costs
	Research and development costs that are reimbursable under collaboration agreements are included as a reduction of research and development expenses. The Company records these reimbursements as a reduction of research and development expenses as the Company’s partner in the collaboration agreement has the financial risks and responsibility for conducting these research and development activities.
	Stock-Based Compensation
	The Company has a stock incentive plan, the Immunomedics, Inc. 2006 Stock Incentive Plan, as amended, that includes a discretionary grant program, a stock issuance program and an automatic grant program. The plan was established to promote the interests of the Company, by providing eligible persons with the opportunity to acquire a proprietary interest in the Company as an incentive to remain with the organization and to align the employee’s interest with our stockholders. This plan is described more fully in Note 7 the audited financial statements included in our Annual Report on Form 10-K for the year ended June 30, 2014 and Note 5 to the condensed consolidated financial statements in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, included elsewhere herein.
	The grant-date fair value of stock awards is based upon the underlying price of the stock on the date of grant. The grant-date fair value of stock option awards must be determined using an option pricing model. Option pricing models require the use of estimates and assumptions as to (a) the expected term of the option, (b) the expected volatility of the price of the underlying stock and (c) the risk-free interest rate for the expected term of the option. The Company uses the Black-Scholes-Merton option pricing formula for determining the grant-date fair value of such awards.
	The expected term of the option is based upon the contractual term and expected employee exercise and expected post-vesting employment termination behavior. The expected volatility of the price of the underlying stock is based upon the historical volatility of the Company’s stock computed over a period of time equal to the expected term of the option. The risk free interest rate is based upon the implied yields currently available from the U.S. Treasury yield curve in effect at the time of the grant. Pre-vesting forfeiture rates are estimated based upon past voluntary termination behavior and past option forfeitures.
	The following table sets forth the weighted-average assumptions used to calculate the fair value of options granted for the three-month periods ended September 30, 2014 and 2013:
			Three-Month Period Ended September 30,
			2014		2013
	Expected dividend yield		0%		0%
	Expected option term (years)		5.07		5.2
	Expected stock price volatility		61%		67%
	Risk-free interest rate		1.60%		1.56%-1.74%
	Changes in any of these assumptions could impact, potentially materially, the amount of expense recorded in future periods related to stock-based awards.
	Income Taxes
	The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective tax bases. The Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change. The Company has recorded a full valuation allowance against its net deferred tax assets as of September 30, 2014.
	Income taxes were provided for profitable foreign jurisdictions at the estimated annual tax rate during the three-month periods ended September 30, 2014 and 2013. The Company’s U.S. operations reported a net loss for the three-month periods ended September 30, 2014 and 2013, resulting in a tax benefit that was fully offset by a valuation allowance.
	The Company has no liability for uncertain tax positions as of September 30, 2014.
	Net Loss Per Share Allocable to Common Stockholders
	Net loss per basic and diluted common share allocable to common stockholders is based on the net loss for the relevant period, divided by the weighted-average number of common shares outstanding during the period. For purposes of the diluted net loss per common share calculations, the exercise or conversion of all potential common shares is not included because their effect would have been anti-dilutive, due to the net loss recorded for the three-month periods ended September 30, 2014 and 2013. The common stock equivalents excluded from the diluted per share calculation are 7,461,763 and 7,708,560 shares at September 30, 2014 and 2013, respectively.
	Comprehensive Loss
	Comprehensive loss consists of net loss, unrealized loss on available for sale securities and foreign exchange translation adjustments and is presented in the condensed consolidated statements of comprehensive loss.
	Reclassification
Certain prior period balances have been reclassified to conform to the current period presentation.
Accounting Pronouncements
In August 2014, the FASB issued Accounting Standard Update (“ASU”) 2014-15, “Presentation of Financial Statements – Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This guidance clarifies that an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. The amendments in this update are effective for annual reporting periods ending after December 15, 2016, and annual and interim periods thereafter, and early application is permitted. The Company is assessing ASU 2014-15’s impact and will adopt it when effective.
In June 2014, the FASB issued ASU 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. This guidance clarifies that awards with these provisions should be treated as performance conditions that affect vesting, and do not impact the award’s estimated grant-date fair value. The amendments in this update are effective for annual reporting periods beginning after December 31, 2015, including interim periods, and early application is permitted. The Company is assessing ASU 2014-12’s impact and will adopt it when effective.
In June 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers”. This ASU was initiated as a joint project by the FASB and the International Accounting Standards Board (“IASB”) to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS. For a public company, the amendments in this update are effective for annual reporting periods beginning after December 15, 2016, including interim periods, and early application is not permitted for public companies. The Company is assessing ASU 2014-09’s impact and will adopt it when effective.

Marketable_Securities

Marketable Securities	3 Months Ended
	Sep. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Marketable Securities	'
	3	Marketable Securities
	Immunomedics adopted Accounting Standards Codification No. 320, Accounting for Investments - Debt and Equity Securities, to account for investments in marketable securities. Under this accounting standard, securities for which there are no positive intent and ability to hold to maturity, the securities are classified as available-for-sale and are carried at fair value. Unrealized holding gains and losses, which are deemed to be temporary, on securities classified as available-for-sale are carried as a separate component of accumulated other comprehensive income (loss). Immunomedics considers all of its current investments to be available-for-sale. Marketable securities at September 30, 2014 consist of the following (in thousands):
			Amortized		Gross		Gross			Fair Value
			Cost		Unrealized		Unrealized
					Gain		(Loss)
	September 30, 2014
	U.S. Treasury Bonds		$	5,529	$	1	$	—		$	5,530
	U.S. Government Sponsored Agencies			7,453		—		—			7,453
	Corporate Debt Securities			13,564		5		(10	)		13,559
			$	26,546	$	6	$	(10	)	$	26,542
	Maturities of debt securities classified as available-for-sale were as follows at September 30, 2014 (in thousands):
			Fair Value		Net Carrying
					Amount
	Due within one year		$	24,943	$	25,027
	Due after one year through five years			1,599		1,610
			$	26,542	$	26,637
	Marketable securities at June 30, 2014 consist of the following (in thousands):
			Amortized		Gross		Gross			Fair Value
			Cost		Unrealized		Unrealized
					Gain		(Loss)
	June 30, 2014
	U.S. Treasury Bonds		$	8,537	$	1	$	(1	)	$	8,537
	U.S. Government Sponsored Agencies			7,458		—		(1	)		7,457
	Corporate Debt Securities			18,876		12		(11	)		18,877
			$	34,871	$	13	$	(13	)	$	34,871
	Maturities of debt securities classified as available-for-sale were as follows at June 30, 2014 (in thousands):
			Fair Value		Net Carrying
					Amount
	Due within one year		$	25,336	$	25,449
	Due after one year through five years			9,535		9,603
			$	34,871	$	35,052
	For the three-month period ended September 30, 2014, $8.3 million of the Company’s debt securities and municipal bonds either matured or were sold. There were no such sales or maturities during the three-month period ended September 30, 2013.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	4	Stockholders’ Equity
	Accumulated Other Comprehensive Income
	The components of accumulated other comprehensive income were as follows:
			Currency			Net Unrealized			Accumulated Other
			Translation			(Losses) Gains on			Comprehensive
			Adjustments			Available-for-Sale			Income
						Securities
	Balance, July 1, 2014		$	261,924		$	(87	)	$	261,837
	Other comprehensive income (loss) before reclassifications			(178,130	)		2,763			(175,367	)
	Amounts reclassified from accumulated other comprehensive income(a)			—			(7,215	)		(7,215	)
	Net current-period other comprehensive loss			(178,130	)		(4,452	)		(182,582	)
	Balance, September 30, 2014		$	83,794		$	(4,539	)	$	79,255
	Balance, July 1, 2013		$	161,830		$	—		$	161,830
	Other comprehensive income (loss) before reclassifications			72,367			(4,960	)		67,407
	Amounts reclassified from accumulated other comprehensive income(a)			—			—			—
	Net current-period other comprehensive income (loss)			72,367			(4,960	)		67,407
	Balance, September 30, 2013		$	234,197		$	(4,960	)	$	229,237
	All components of accumulated other comprehensive income are net of tax, except currency translation adjustments, which exclude income taxes related to indefinite investments in foreign subsidiaries.
	(a)	For the three month period ended September 30, 2014, $7,215 was reclassified from accumulated other comprehensive income to interest and other income. There was no such reclassification during the three month period ended September 30, 2013.

Stock_Incentive_Plan

Stock Incentive Plan	3 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock Incentive Plan	'
	5	Stock Incentive Plan
	The Company believes that awards under the Immunomedics, Inc. 2006 Stock Incentive Plan (the “Plan”) better align the interests of its employees with those of its stockholders. Option awards are generally granted with an exercise price equal to the market price of the Company’s common stock at the date of grant; those option awards generally vest based on four years of continuous service and have seven year contractual terms. Option awards that are granted to non-employee Board members under the annual option grant program are granted with an exercise price equal to the market price of the Company’s common stock at the date of grant, are vested immediately and have seven year contractual terms. At September 30, 2014, there were 9,857,606 shares of common stock reserved for possible future issuance under the Plan, both currently outstanding (6,461,763 shares) and which were available to be issued for future grants (3,395,843 shares).
	The weighted average fair value at the date of grant for options granted during the three-month periods ended September 30, 2014 and 2013 were $1.75 and $3.07 per share, respectively. The Company uses historical data to estimate employee forfeitures for employees, executive officers and outside directors. The expected term of options granted represents the period of time that options granted are expected to be outstanding and the expected stock price volatility is based on the Company’s daily stock trading history. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.
	Information concerning options for the three-month period ended September 30, 2014 is summarized as follows:
			Shares			Weighted		Weighted		Aggregate
						Average		Average		Intrinsic
						Exercise		Remaining		Value
						Price		Contractual
								Life
	Outstanding, July 1, 2014			5,308,617		$	3.41
	Granted			488,719		$	3.32
	Cancelled or forfeited			(280,500	)	$	4.4
	Outstanding, September 30, 2014			5,516,836		$	3.35		3.67	$	3,445,495
	Exercisable, September 30, 2014			4,027,480		$	3.16		2.76	$	3,142,578
	A summary of the Company’s non-vested restricted and performance stock units at July 1, 2014, and changes during the three-month period ended September 30, 2014 are presented below:
	Outstanding Non-Vested Restricted and Performance Stock Units		Number of
			Awards
	Non-vested at July 1, 2014			788,364
	Restricted Units Granted			226,657
	Vested			(397,364	)
	Exercised			(70,094	)
	Non-vested at September 30, 2014			547,563
	The Company has 2,036,919 non-vested options, restricted and performance stock units outstanding as of September 30, 2014. As of September 30, 2014, there was $3.0 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is being recognized over a weighted-average period of 3.0 years. The Company recorded $0.6 million and $0.4 million for total stock-based compensation expense for employees, executive officers and non-employee Board members for the three-month periods ended September 30, 2014 and 2013, respectively.
	Each non-employee Board member who continues to serve shall receive on the date of the annual stockholders meeting an annual grant of non-qualified stock options and restricted stock units, each equal in value to $45 thousand. The Company recorded $45 thousand and $55 thousand for stock-based compensation expense for these non-employee Board members restricted stock units for the three-month periods ended September 30, 2014 and 2013, respectively.
	On August 14 2014, the Company awarded an additional 226,657 restricted stock units to certain executive officers of the Company at the market price on that date ($3.32 per share). These restricted stock units will vest over a four year period. As of September 30, 2014, there was $1.8 million of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Plan for these executive officers, excluding performance stock units. The cost is being recognized over a weighted-average period of 2.8 years. The Company recorded $0.2 million and $0.1 million for stock-based compensation expense for restricted stock units for each of the three-month periods ended September 30, 2014 and 2013, respectively.
	On August 16, 2013, the Company also awarded certain executive officers Performance Units of up to 389,864 units of restricted stock units which are subject to attainment of certain performance milestones as well as certain continued service requirements. All or a portion of the Performance Units vest based upon the level of achievement of the milestones set forth in each agreement, which is expected to be achieved within five years of the grant date. The Performance Units that vest based upon attainment of the Performance Milestone will be exercised based on a percentage basis on the attainment of anniversary dates. As of September 30, 2014, there are 389,864 Performance Units available if all performances are achieved within five years of grant date. The Company recorded $32 thousand and $0.2 million for the stock-based compensation for the three-month periods ended September 30, 2014 and 2013, respectively. There is $0.9 million of total unrecognized compensation cost related to these non-vested Performance Units granted as of September 30, 2014. That cost is being recognized over a weighted-average period of 2.4 years. The unrecognized compensation cost is subject to modification on a quarterly basis based on review of performance probability and requisite achievement periods.

Geographic_Segments

Geographic Segments	3 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Geographic Segments	'
	6	Geographic Segments
	Immunomedics manages its operations as one line of business of researching, developing, manufacturing and marketing biopharmaceutical products, particularly antibody-based products for cancer, autoimmune and other serious diseases, and it currently reports as a single industry segment. Immunomedics conducts its research and development activities primarily in the United States. Immunomedics markets and sells LeukoScan throughout Europe and in certain other countries outside the United States.
	The following table presents financial information based on the geographic location of the facilities of Immunomedics as of and for the three-months ended September 30, 2014 and 2013 ($ in thousands):
			As of and for the
			Three Months Ended
			September 30, 2014
			United			Europe			Total
			States
	Total assets		$	35,017		$	2,799		$	37,816
	Property and equipment, net			2,086			—			2,086
	Revenues			368			704			1,072
	(Loss) income before taxes			(12,455	)		24			(12,431	)
			As of and for the
			Three Months Ended
			September 30, 2013
			United			Europe			Total
			States
	Total assets		$	38,547		$	2,663		$	41,210
	Property and equipment, net			2,074			—			2,074
	Revenues			4,949			549			5,498
	Loss before taxes			(5,187	)		(35	)		(5,222	)

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	7	Related Party Transactions
	Certain of the Company’s affiliates, including members of its senior management and its Board of Directors, as well as their respective family members and other affiliates, have relationships and agreements among themselves as well as with the Company and its affiliates, that create the potential for both real, as well as perceived, conflicts of interest. These include Dr. David M. Goldenberg, the Chairman of the Board of Directors and Chief Medical Officer and Chief Scientific Officer, Ms. Cynthia L. Sullivan, the President and Chief Executive Officer, who is the wife of Dr. David M. Goldenberg, and certain companies with which the Company does business, including the Center for Molecular Medicine and Immunology (“CMMI”), and the Company’s majority-owned subsidiary IBC.
	Immunomedics, Inc. leases approximately 1,000 square feet of its Morris Plains, NJ facility to CMMI at a cost of approximately $30 thousand per year. The Company incurred $10 thousand and $5 thousand of legal expenses on behalf of CMMI for patent related matters for each of the three-month periods ended September 30, 2014 and 2013. The Company has first rights to license those patents, and may decide whether or not to support them. However, any inventions made independently of the Company by CMMI are the property of CMMI. On occasion, CMMI engages in research contracts on behalf of Immunomedics, Inc. However, for the three-month periods ended September 30, 2014 and 2013 there were no research related activities charged to the Company.
	For the three-month periods ended September 30, 2014 and 2013, Dr. Goldenberg received approximately $21 thousand and $20 thousand, respectively, in compensation for his services to IBC.

License_and_Collaboration_Agre

License and Collaboration Agreements	3 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
License and Collaboration Agreements	'
	8	License and Collaboration Agreements
	Takeda Pharmaceutical/Nycomed GmbH
	On July 11, 2008, the Company entered into the Nycomed Agreement with Nycomed providing Nycomed a worldwide license to develop, manufacture and commercialize veltuzumab, the Company’s humanized anti-CD20 antibody, in the subcutaneous formulation, for the treatment of all non-cancer indications. The Company retained the rights to develop, manufacture and commercialize veltuzumab in the field of oncology. On September 30, 2011, Takeda Pharmaceutical Company Limited completed its acquisition of Nycomed and made Nycomed a wholly owned subsidiary of Takeda (“Takeda-Nycomed”).
	Takeda-Nycomed was solely responsible for the development, manufacturing, regulatory approval and commercialization of veltuzumab and the development, manufacturing and regulatory approval of the subcutaneous formulation for all non-cancer indications. The Company’s major obligations were to complete the research and development activities as specified in the Nycomed Agreement and to manufacture and supply veltuzumab to Takeda-Nycomed for the quantity of materials for the period of time specified in the Nycomed Agreement. The Company completed all of its obligations under the agreement, namely its manufacturing and supply obligations and its responsibilities in the Phase 1/2 study in immune thrombocytopenic purpura (“ITP”).
	On October 3, 2013, the Company received notification from Takeda Pharmaceutical Company Limited/Nycomed GmbH of termination of the Nycomed Agreement. The notification was received subsequent to the Company’s filing of arbitration proceedings in an effort to resolve the dispute the Company has with Nycomed and Takeda concerning delays in the development of veltuzumab, which the Company argues is a material breach of the licensing agreement. As a result of the termination, all rights to veltuzumab revert to the Company. All parties have had discussions regarding the transition of veltuzumab back to the Company and certain materials have been returned to the Company. In addition, the Company has continued to pursue the arbitration procedure to address its claim for damages due to, among other things, delays in the development of veltuzumab.
	On October 11, 2013, Takeda and Takeda-Nycomed filed their Statement of Defense and Counterclaims alleging, among other things, that the Company wrongfully terminated the licensing agreement and caused Takeda and Takeda-Nycomed to suffer significant damages and delays in developing veltuzumab. The Company responded by filing its own Statement of Defense on November 12, 2013, denying Takeda and Takeda-Nycomed’s allegations and contesting Takeda or Takeda-Nycomed’s rights to any relief. An arbitrator was appointed later that month. On December 20, 2013 the arbitrator issued a pre-hearing scheduling order and the arbitration proceeded in accordance with that schedule as subsequently amended. The hearing portion of the arbitration process was completed on August 21, 2014. Each party’s counsel filed final post-hearing submissions on October 17, 2014. The decision by the arbitrator is expected within two months of the post-hearing submissions.
	UCB, S.A.
	On May 9, 2006, the Company entered into an agreement with UCB, S.A. referred to herein as UCB, providing UCB an exclusive worldwide license to develop, manufacture, market and sell epratuzumab for the treatment of all non-cancer indications referred to herein as the UCB Agreement. Under the terms of the UCB Agreement, the Company received from UCB a non-refundable cash payment totaling $38.0 million. On December 27, 2011, the Company entered into the Amendment Agreement with UCB referred to herein as the Amendment Agreement. The Amendment Agreement provided UCB the right to sublicense epratuzumab, subject to obtaining the Company’s prior consent, to a third party for the United States and certain other territories. As of September 30, 2014, UCB has not executed a sublicense agreement with a third-party.
	The Company also issued to UCB on December 27, 2011 a 5-year warrant to purchase one million shares of the Company’s common stock, par value $0.01 per share, at an exercise price of $8.00 per share. In exchange for the right to sublicense its rights in epratuzumab to a third party and the warrant issuance, the Company received a non-refundable cash payment of $30.0 million in January 2012. Further, under the terms of the Amendment Agreement, UCB surrendered its buy-in right with respect to epratuzumab in the field of oncology, which had been granted under the UCB Agreement.
	Collectively, pursuant to the UCB Agreement and the Amendment Agreement the Company is entitled to receive (i) up to $145.0 million in cash payments and $20.0 million in equity investments in regulatory milestone payments and (ii) up to $260.0 million related to the achievement of specified product sales milestones. The Company is also entitled to product royalties ranging from a mid-teen to mid-twenty percentage of aggregate annual net sales under the UCB Agreement and Amendment Agreement during the product royalty term. No development milestone, commercialization milestone or royalty payments were achieved through September 30, 2014. There can be no assurance that the development or commercialization milestones or royalty payment thresholds under the UCB Agreement and Amendment Agreement will be met and therefore there can be no assurance that the Company will receive such future payments.
	The Agreement commenced on May 9, 2006 and shall terminate in accordance with the terms thereof or by mutual written consent, unless UCB decides to cease all development and commercialization of epratuzumab pursuant to the Agreement. Either the Company or UCB has the right to terminate the Agreement by notice in writing to the other party upon or after any material breach of the Agreement by the other party, if the other party has not cured the breach within 60 days after written notice to cure has been given, with certain exceptions. Upon termination of the Agreement, among other things, all rights and licenses granted by the Company to UCB shall terminate, all rights of UCB under the Immunomedics Patent Rights (as defined in the Agreement) and Immunomedics Know-How (as defined in the Agreement) shall revert to the Company, and UCB shall cease all use of the Immunomedics Patent Rights and Immunomedics Know-How. Further, all regulatory filings and Approvals (as defined in the Agreement) and any other documents relating to or necessary to further develop and commercialize the Licensed Compound (as defined in the Agreement) and Licensed Products (as defined in the Agreement), including, without limitation, all sublicenses granted by UCB, and all of UCB’s right, title and interest therein and thereto, shall be assigned to the Company at the Company’s option. No additional amounts shall be payable on events occurring after the effective date of termination.
	The Bayer Group (formerly Algeta ASA)
	In January 2013, the Company entered into a collaboration agreement with Algeta ASA for the development of epratuzumab to be conjugated with Algeta’s proprietary thorium-227 alpha-pharmaceutical payload. On August 2, 2013, an amendment to the collaboration agreement was entered into between the two companies modifying certain delivery and supply parameters. Under the terms of this agreement, as amended, the Company is required to manufacture and supply clinical-grade epratuzumab to Algeta, which has rights to evaluate the potential of a Targeted Thorium Conjugate (TTC), linking thorium-227 to epratuzumab, for the treatment of patients with cancer. Algeta will fund all non-clinical and clinical development costs up to the end of Phase 1 clinical testing. Upon successful completion of Phase 1 testing, the parties shall negotiate terms for a license agreement at Algeta’s request. The Company and Algeta agreed to certain parameters in the collaboration agreement. Under the terms of the collaboration agreement, as amended, Immunomedics received an upfront cash payment and other payments which have been recognized upon the Company fulfilling its obligations under the collaboration agreement. For the three-month period ended September 30, 2013, the Company recognized $4.6 million of revenue under this arrangement, which has been included in license fee and other revenues, while the related costs of $1.2 million is included in cost of license fee and other revenue. As of fiscal year ended June 30, 2014, the Company recognized all of the initial cash payments as revenue as the aspects of delivery for the clinical supply material have been satisfied. On March 6, 2014, The Bayer Group (“Bayer”) completed its voluntary takeover of 98.2% shares and voting rights in Algeta ASA which made Algeta ASA a majority-owned subsidiary of Bayer. Bayer has subsequently acquired the remaining shares from the minority shareholders and the program with Immunomedics has been formally transferred to Bayer (Algeta).

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	9	Commitments and Contingencies
	Employment Contracts
	Effective July 1, 2011, the Company entered into the Third Amended and Restated Employment Agreement with Dr. Goldenberg for his service to the Company as the Chief Scientific Officer and Chief Medical Officer (the “Goldenberg Agreement”), which terminates July 1, 2016. This agreement covers aspects of his compensation as well as duties and responsibilities at Immunomedics. Under this agreement Dr. Goldenberg’s annual base salary is at a minimum of $0.5 million, which shall be reviewed annually for appropriate increases by the Board of Directors or the Compensation Committee (increased 3.5% to $0.6 million for the 2015 fiscal year). Dr. Goldenberg will also be eligible to participate in any Company incentive compensation plan in place for its senior level executives and is eligible to receive an annual discretionary bonus based upon certain performance standards to be determined by the Compensation Committee. Dr. Goldenberg’s annual bonus target is 50% of his annual base salary, subject to achievement of performance goals, with a potential payout from 0 to 150% of the target amount.
	Under the Goldenberg Agreement, Dr. Goldenberg is eligible to receive certain additional incentive compensation during the agreement term, including being eligible to receive royalty payments from royalties received by the Company. For each fiscal year, the Company shall pay Dr. Goldenberg a sum equal to a percentage of the annual royalties the Company receives on each of the products for which Dr. Goldenberg is an inventor, and all products using, related to or derived from products for which Dr. Goldenberg is an inventor. The percentage of royalties that the Company will pay to Dr. Goldenberg on each patented product will be determined based on the percentage of royalties that the Company receives from external third parties.
	Under the terms of the Goldenberg Agreement, the Company makes a minimum quarterly payment of $37.5 thousand to Dr. Goldenberg during each of the fiscal years during the Goldenberg Agreement, as an advance against the amounts due as additional incentive compensation, royalty payments and dispositions of undeveloped assets. For the three-month periods ended September 30, 2014 and 2013, no additional incentive compensation payments were made to Dr. Goldenberg other than the $37.5 thousand minimum quarterly payments.
	On July 1, 2014, the Company and Cynthia L. Sullivan entered into the Fifth Amended and Restated Employment Agreement pertaining to Ms. Sullivan’s service as the Company’s President and Chief Executive Officer. The Amended Sullivan Agreement shall terminate on July 1, 2017. Ms. Sullivan’s annual base salary under the agreement is $0.6 million, which shall be reviewed annually for appropriate increases by the Board of Directors or the Compensation Committee (increased by 3.5% for the 2015 fiscal year). Ms. Sullivan is also eligible to participate in the Company’s incentive compensation plan in place for its senior level executives. Ms. Sullivan’s annual bonus target is 50% of her base salary, subject to achievement of performance goals, with a potential payout from 0 to 150% of the target amount. Ms. Sullivan will also be eligible to receive equity compensation awards under the Company’s 2006 Stock Incentive Plan, or any such successor equity compensation plan as may be in place from time to time.
	Legal Matters
	The following is a summary of legal matters that are outstanding:
	Former Licensing Partner:
	On October 3, 2013, the Company received notification from Takeda Pharmaceutical Company Limited/Nycomed GmbH of termination of the License and Collaboration Agreement that it entered into with Nycomed which provided Nycomed a worldwide license to develop, manufacture and commercialize veltuzumab, in the subcutaneous formulation, for the treatment of all non-cancer indications, referred to herein as the Nycomed Agreement. The notification was received subsequent to the Company’s filing of arbitration proceedings in an effort to resolve the dispute it has with Nycomed and Takeda concerning delays in the development of veltuzumab, which the Company argues is a material breach of the Nycomed Agreement. As a result of the termination, all rights to veltuzumab revert to the Company. All parties have had discussions regarding the transition of veltuzumab back to the Company and certain materials have been returned to the Company. In addition, the Company has continued to pursue the arbitration procedure to address its claim for damages due to, among other things, delays in the development of veltuzumab.
	On October 11, 2013, Takeda and Takeda-Nycomed filed their Statement of Defense and Counterclaims alleging, among other things, that the Company wrongfully terminated the licensing agreement and caused Takeda and Takeda-Nycomed to suffer significant damages and delays in developing veltuzumab. The Company responded by filing its own Statement of Defense on November 12, 2013, denying Takeda and Takeda-Nycomed’s allegations and contesting Takeda or Takeda-Nycomed’s rights to any relief. An arbitrator was appointed later that month. On December 20, 2013 the arbitrator issued a pre-hearing scheduling order, and the arbitration proceeded in accordance with that schedule as subsequently amended. The hearing portion of the arbitration process was completed on August 21, 2014. Each party’s counsel filed a final post-hearing submission on October 17, 2014. The decision by the arbitrator is expected within two months of the post-hearing submissions.
	The Company does not believe these matters, even if adversely adjudicated or settled, would have a material adverse effect on its consolidated financial condition, results of operations or cash flows.
	Shareholder complaints:
	Two separate shareholder derivative complaints have been filed against the Company. First, on March 24, 2014, a complaint styled Kops v. Goldenberg, et al., was filed in the Superior Court of New Jersey, Chancery Division, General Equity Part, Morris County. Second, on April 18, 2014, a complaint styled Breitman v. Sullivan, et al., was filed in the United States District Court for the District of New Jersey. The complaints allege, among other things, that the Company and certain directors and officers breached their fiduciary duties for disseminating false and misleading information relating to the termination of the Nycomed Agreement. In particular, the complaints allege that defendants failed to make timely disclosure concerning a dispute concerning a delay in the development of veltuzumab. On October 9, 2013, the Company announced that the Nycomed Agreement was terminated. The complaints allege that the breaches in fiduciary duties by the directors and officers caused damages to the Company and stockholders, including a decline in value of the Company’s common stock, increased investigatory and litigation costs, and exposure to civil liability as a result of a pending securities fraud class action suit. Plaintiffs bring the derivative actions to recover damages against the directors and officers for the benefit of the Company, and to require the Company to reform and improve its corporate governance and internal procedures. Both derivative actions have been stayed pending the outcome of a related putative class action lawsuit, described below. The defendants believe that the allegations in the derivative complaints are without merit and intend to defend the lawsuits vigorously; however, there can be no assurance regarding the ultimate outcome of these lawsuits.
	A putative class action lawsuit, styled Nasyrova v. Immunomedics, Inc., was filed on February 27, 2014 in the United States District Court for the District of New Jersey. The lawsuit alleges that the Company and certain of its current and former officers and directors failed to disclose and/or made material misstatements in the Company’s public filings relating to the termination of the Nycomed Agreement. In particular, the complaint alleges that defendants failed to make timely disclosure concerning a dispute concerning a delay in the development of veltuzumab. On October 9, 2013, the Company announced that the Nycomed Agreement was terminated. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On June 24, 2014 the District Court entered an order appointing John Neff as lead plaintiff and The Rosen Law Firm, P.A. as lead counsel. Lead plaintiff and lead counsel thereafter filed an Amended Class Action Complaint on August 8, 2014. The defendants filed a motion to dismiss the Amended Class Action Complaint on September 22, 2014. The defendants believe that the allegations in the class action complaint are without merit and intend to defend the lawsuit vigorously; however, there can be no assurance regarding the ultimate outcome of this lawsuit.
	Immunomedics is also a party to various claims and litigation arising in the normal course of business, which includes some or all of certain of its patents. While it is not possible to determine the outcome of these matters, the Company believes that the resolution of all such matters will not have a material adverse effect on its consolidated financial position or liquidity, but could possibly be material to its consolidated results of operations in any one accounting period.

Subsequent_Event

Subsequent Event	3 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Event	'
	10	Subsequent Event
	On October 1, 2014, the Company’s registration statement on Form S-3, as filed with the U.S. Securities and Exchange Commission (the “SEC”) on September 16, 2014, was deemed effective using a “shelf” registration process. Under this shelf registration statement, the Company may issue, in one or more offerings, any combination of common stock, preferred stock senior or subordinated debt securities, warrants, or units, up to a total dollar amount of $130.0 million.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Principles of Consolidation and Presentation	'
	Principles of Consolidation and Presentation
	The condensed consolidated financial statements include the accounts of Immunomedics and its subsidiaries. Noncontrolling interests in consolidated subsidiaries in the condensed consolidated balance sheets represent minority stockholders’ proportionate share of the equity (deficit) in such subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Financial Instruments	'
	Financial Instruments
	The carrying amounts of cash and cash equivalents, other current assets and current liabilities approximate fair value due to the short-term maturity of these instruments. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.
Estimated Fair Value of Financial Instruments	'
	Estimated Fair Value of Financial Instruments
	The Company has categorized its financial assets, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. The Company does not have any financial liabilities that are required to be measured at fair value on a recurring basis. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
	Financial assets recorded on the condensed consolidated balance sheets as of September 30, 2014 and June 30, 2014 are categorized based on the inputs to the valuation techniques as follows (in thousands):
		•		Level 1 – Financial assets whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the company has the ability to access at the measurement date (examples include active exchange-traded equity securities and most U.S. Government and agency securities).
		•		Level 2 – Financial assets whose value are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.
		•		Level 3 – Financial assets whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset.
			($ in thousands)
	September 30, 2014		Level 1			Level 2		Level 3		Total
	Money Market Funds		$	1,264		$	—	$	—	$	1,264
	Marketable Securities:
	U.S. Treasury Bonds			5,530			—		—		5,530
	U.S. Government Sponsored Agencies			7,453			—		—		7,453
	Corporate Debt Securities			13,559			—		—		13,559
	Total		$	27,806		$	—	$	—	$	27,806
			($ in thousands)
	June 30, 2014		Level 1			Level 2		Level 3		Total
	Money Market Funds		$	367		$	—	$	—	$	367
	Marketable Securities:
	U.S. Treasury Bonds			8,537			—		—		8,537
	U.S. Government Sponsored Agencies			7,457			—		—		7,457
	Corporate Debt Securities			18,877			—		—		18,877
	Total		$	35,238		$	—	$	—	$	35,238
	The money market funds noted above are included in cash and cash equivalents.
Marketable Securities	'
	Marketable Securities
	Marketable securities, all of which are available-for-sale, consist of corporate debt securities and municipal bonds. Marketable securities are carried at fair value, with unrealized gains and losses, net of related income taxes, reported as accumulated other comprehensive income, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses, and declines in value judged to be other-than-temporary on available-for-sale securities are included in the determination of net (loss) income and are included in interest and other income (net), at which time the average cost basis of these securities are adjusted to fair value. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included interest and other income (net).
Inventory	'
	Inventory
	Inventory, which consists only of the finished product of LeukoScan®, is stated at the lower of cost (which approximates first-in, first-out) or market, and includes materials, labor and manufacturing overhead.
Revenue Recognition	'
	Revenue Recognition
	The Company has accounted for revenue arrangements that include multiple deliverables as a separate unit of accounting if both of the following criteria are met: a) the delivered item has value to the customer on a standalone basis, and b) if the right of return exists, delivery of the undelivered items is considered probable and substantially in the control of the vendor. If these criteria are not met, the revenue elements must be considered a single unit of accounting for purposes of revenue recognition. The Company allocates revenue consideration, excluding contingent consideration, based on the relative selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Relative selling prices are determined using vendor specific objective evidence, if it exists; otherwise third-party evidence or the Company’s best estimate of selling price is used for each deliverable.
	Payments received under contracts to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Payments received in advance that are related to future performance are deferred and recognized as revenue when the research projects are performed. Upfront nonrefundable fees associated with license and development agreements where the Company has continuing involvement in the agreement are recorded as deferred revenue and recognized over the estimated service period. The Company estimates the period of continuing involvement based on the best evidential matter available at each reporting period. If the estimated service period is subsequently modified, the period over which the upfront fee is recognized is modified accordingly on a prospective basis.
	In order to determine the revenue recognition for contingent milestones, the Company evaluates the contingent milestones using the criteria as provided by the Financial Accounting Standards Boards (“FASB”) guidance on the milestone method of revenue recognition, as explained in ASU 2010-17, “Milestone Method of Revenue Recognition”, at the inception of a collaboration agreement. The criteria requires that (i) the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from the Company’s activities to achieve the milestone, (ii) the milestone be related to past performance, and (iii) the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved. Royalties are recognized as earned in accordance with the terms of various research and collaboration agreements.
	Revenue from the sale of diagnostic products is recorded when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed and determinable or collectability is reasonably assured. Allowances, if any, are established for uncollectible amounts, estimated product returns and discounts. Since allowances are recorded based on management’s estimates, actual amounts may be different in the future.
Research and Development Costs	'
	Research and Development Costs
	Research and development costs are expensed as incurred. Costs incurred for clinical trials for patients and investigators are expensed as services are performed in accordance with the agreements in place with their clinical sites.
Reimbursement of Research & Development Costs	'
	Reimbursement of Research & Development Costs
	Research and development costs that are reimbursable under collaboration agreements are included as a reduction of research and development expenses. The Company records these reimbursements as a reduction of research and development expenses as the Company’s partner in the collaboration agreement has the financial risks and responsibility for conducting these research and development activities.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company has a stock incentive plan, the Immunomedics, Inc. 2006 Stock Incentive Plan, as amended, that includes a discretionary grant program, a stock issuance program and an automatic grant program. The plan was established to promote the interests of the Company, by providing eligible persons with the opportunity to acquire a proprietary interest in the Company as an incentive to remain with the organization and to align the employee’s interest with our stockholders. This plan is described more fully in Note 7 the audited financial statements included in our Annual Report on Form 10-K for the year ended June 30, 2014 and Note 5 to the condensed consolidated financial statements in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, included elsewhere herein.
	The grant-date fair value of stock awards is based upon the underlying price of the stock on the date of grant. The grant-date fair value of stock option awards must be determined using an option pricing model. Option pricing models require the use of estimates and assumptions as to (a) the expected term of the option, (b) the expected volatility of the price of the underlying stock and (c) the risk-free interest rate for the expected term of the option. The Company uses the Black-Scholes-Merton option pricing formula for determining the grant-date fair value of such awards.
	The expected term of the option is based upon the contractual term and expected employee exercise and expected post-vesting employment termination behavior. The expected volatility of the price of the underlying stock is based upon the historical volatility of the Company’s stock computed over a period of time equal to the expected term of the option. The risk free interest rate is based upon the implied yields currently available from the U.S. Treasury yield curve in effect at the time of the grant. Pre-vesting forfeiture rates are estimated based upon past voluntary termination behavior and past option forfeitures.
	The following table sets forth the weighted-average assumptions used to calculate the fair value of options granted for the three-month periods ended September 30, 2014 and 2013:
			Three-Month Period Ended September 30,
			2014		2013
	Expected dividend yield		0%		0%
	Expected option term (years)		5.07		5.2
	Expected stock price volatility		61%		67%
	Risk-free interest rate		1.60%		1.56%-1.74%
	Changes in any of these assumptions could impact, potentially materially, the amount of expense recorded in future periods related to stock-based awards.
Income Taxes	'
	Income Taxes
	The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective tax bases. The Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change. The Company has recorded a full valuation allowance against its net deferred tax assets as of September 30, 2014.
	Income taxes were provided for profitable foreign jurisdictions at the estimated annual tax rate during the three-month periods ended September 30, 2014 and 2013. The Company’s U.S. operations reported a net loss for the three-month periods ended September 30, 2014 and 2013, resulting in a tax benefit that was fully offset by a valuation allowance.
	The Company has no liability for uncertain tax positions as of September 30, 2014.
Net Loss Per Share Allocable to Common Stockholders	'
	Net Loss Per Share Allocable to Common Stockholders
	Net loss per basic and diluted common share allocable to common stockholders is based on the net loss for the relevant period, divided by the weighted-average number of common shares outstanding during the period. For purposes of the diluted net loss per common share calculations, the exercise or conversion of all potential common shares is not included because their effect would have been anti-dilutive, due to the net loss recorded for the three-month periods ended September 30, 2014 and 2013. The common stock equivalents excluded from the diluted per share calculation are 7,461,763 and 7,708,560 shares at September 30, 2014 and 2013, respectively.
Comprehensive Loss	'
	Comprehensive Loss
	Comprehensive loss consists of net loss, unrealized loss on available for sale securities and foreign exchange translation adjustments and is presented in the condensed consolidated statements of comprehensive loss.
Reclassification	'
	Reclassification
	Certain prior period balances have been reclassified to conform to the current period presentation.
Accounting Pronouncements	'
	Accounting Pronouncements
	In August 2014, the FASB issued Accounting Standard Update (“ASU”) 2014-15, “Presentation of Financial Statements – Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This guidance clarifies that an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. The amendments in this update are effective for annual reporting periods ending after December 15, 2016, and annual and interim periods thereafter, and early application is permitted. The Company is assessing ASU 2014-15’s impact and will adopt it when effective.
	In June 2014, the FASB issued ASU 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. This guidance clarifies that awards with these provisions should be treated as performance conditions that affect vesting, and do not impact the award’s estimated grant-date fair value. The amendments in this update are effective for annual reporting periods beginning after December 31, 2015, including interim periods, and early application is permitted. The Company is assessing ASU 2014-12’s impact and will adopt it when effective.
	In June 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers”. This ASU was initiated as a joint project by the FASB and the International Accounting Standards Board (“IASB”) to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS. For a public company, the amendments in this update are effective for annual reporting periods beginning after December 15, 2016, including interim periods, and early application is not permitted for public companies. The Company is assessing ASU 2014-09’s impact and will adopt it when effective.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Financial Assets Recorded on Condensed Consolidated Balance Sheets	'
	Financial assets recorded on the condensed consolidated balance sheets as of September 30, 2014 and June 30, 2014 are categorized based on the inputs to the valuation techniques as follows (in thousands):
		•		Level 1 – Financial assets whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the company has the ability to access at the measurement date (examples include active exchange-traded equity securities and most U.S. Government and agency securities).
		•		Level 2 – Financial assets whose value are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.
		•		Level 3 – Financial assets whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset.
			($ in thousands)
	September 30, 2014		Level 1			Level 2		Level 3		Total
	Money Market Funds		$	1,264		$	—	$	—	$	1,264
	Marketable Securities:
	U.S. Treasury Bonds			5,530			—		—		5,530
	U.S. Government Sponsored Agencies			7,453			—		—		7,453
	Corporate Debt Securities			13,559			—		—		13,559
	Total		$	27,806		$	—	$	—	$	27,806
			($ in thousands)
	June 30, 2014		Level 1			Level 2		Level 3		Total
	Money Market Funds		$	367		$	—	$	—	$	367
	Marketable Securities:
	U.S. Treasury Bonds			8,537			—		—		8,537
	U.S. Government Sponsored Agencies			7,457			—		—		7,457
	Corporate Debt Securities			18,877			—		—		18,877
	Total		$	35,238		$	—	$	—	$	35,238
Schedule of Options Weighted-Average Assumptions	'
	The following table sets forth the weighted-average assumptions used to calculate the fair value of options granted for the three-month periods ended September 30, 2014 and 2013:
			Three-Month Period Ended September 30,
			2014		2013
	Expected dividend yield		0%		0%
	Expected option term (years)		5.07		5.2
	Expected stock price volatility		61%		67%
	Risk-free interest rate		1.60%		1.56%-1.74%

Marketable_Securities_Tables

Marketable Securities (Tables)	3 Months Ended
	Sep. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Components of Marketable Securities	'
	Marketable securities at September 30, 2014 consist of the following (in thousands):
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gain		(Loss)
	September 30, 2014
	U.S. Treasury Bonds	$	5,529	$	1	$	—		$	5,530
	U.S. Government Sponsored Agencies		7,453		—		—			7,453
	Corporate Debt Securities		13,564		5		(10	)		13,559
		$	26,546	$	6	$	(10	)	$	26,542
	Marketable securities at June 30, 2014 consist of the following (in thousands):
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gain		(Loss)
	June 30, 2014
	U.S. Treasury Bonds	$	8,537	$	1	$	(1	)	$	8,537
	U.S. Government Sponsored Agencies		7,458		—		(1	)		7,457
	Corporate Debt Securities		18,876		12		(11	)		18,877
		$	34,871	$	13	$	(13	)	$	34,871
Maturities of Debt Securities Classified as Available-for-Sale	'
	Maturities of debt securities classified as available-for-sale were as follows at September 30, 2014 (in thousands):
		Fair Value		Net Carrying
				Amount
	Due within one year	$	24,943	$	25,027
	Due after one year through five years		1,599		1,610
		$	26,542	$	26,637
	Maturities of debt securities classified as available-for-sale were as follows at June 30, 2014 (in thousands):
		Fair Value		Net Carrying
				Amount
	Due within one year	$	25,336	$	25,449
	Due after one year through five years		9,535		9,603
		$	34,871	$	35,052

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Components of Accumulated Other Comprehensive Income	'
	The components of accumulated other comprehensive income were as follows:
			Currency			Net Unrealized			Accumulated Other
			Translation			(Losses) Gains on			Comprehensive
			Adjustments			Available-for-Sale			Income
						Securities
	Balance, July 1, 2014		$	261,924		$	(87	)	$	261,837
	Other comprehensive income (loss) before reclassifications			(178,130	)		2,763			(175,367	)
	Amounts reclassified from accumulated other comprehensive income(a)			—			(7,215	)		(7,215	)
	Net current-period other comprehensive loss			(178,130	)		(4,452	)		(182,582	)
	Balance, September 30, 2014		$	83,794		$	(4,539	)	$	79,255
	Balance, July 1, 2013		$	161,830		$	—		$	161,830
	Other comprehensive income (loss) before reclassifications			72,367			(4,960	)		67,407
	Amounts reclassified from accumulated other comprehensive income(a)			—			—			—
	Net current-period other comprehensive income (loss)			72,367			(4,960	)		67,407
	Balance, September 30, 2013		$	234,197		$	(4,960	)	$	229,237
	All components of accumulated other comprehensive income are net of tax, except currency translation adjustments, which exclude income taxes related to indefinite investments in foreign subsidiaries.
	(a)	For the three month period ended September 30, 2014, $7,215 was reclassified from accumulated other comprehensive income to interest and other income. There was no such reclassification during the three month period ended September 30, 2013.

Stock_Incentive_Plan_Tables

Stock Incentive Plan (Tables)	3 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of Options	'
	Information concerning options for the three-month period ended September 30, 2014 is summarized as follows:
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Life
	Outstanding, July 1, 2014		5,308,617		$	3.41
	Granted		488,719		$	3.32
	Cancelled or forfeited		(280,500	)	$	4.4
	Outstanding, September 30, 2014		5,516,836		$	3.35		3.67	$	3,445,495
	Exercisable, September 30, 2014		4,027,480		$	3.16		2.76	$	3,142,578
Non-Vested Restricted and Performance Stock Units	'
	A summary of the Company’s non-vested restricted and performance stock units at July 1, 2014, and changes during the three-month period ended September 30, 2014 are presented below:
	Outstanding Non-Vested Restricted and Performance Stock Units	Number of
		Awards
	Non-vested at July 1, 2014		788,364
	Restricted Units Granted		226,657
	Vested		(397,364	)
	Exercised		(70,094	)
	Non-vested at September 30, 2014		547,563

Geographic_Segments_Tables

Geographic Segments (Tables)	3 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Financial Information Based on Geographic Location of Facilities	'
	The following table presents financial information based on the geographic location of the facilities of Immunomedics as of and for the three-months ended September 30, 2014 and 2013 ($ in thousands):
		As of and for the
		Three Months Ended
		September 30, 2014
		United			Europe			Total
		States
	Total assets	$	35,017		$	2,799		$	37,816
	Property and equipment, net		2,086			—			2,086
	Revenues		368			704			1,072
	(Loss) income before taxes		(12,455	)		24			(12,431	)
		As of and for the
		Three Months Ended
		September 30, 2013
		United			Europe			Total
		States
	Total assets	$	38,547		$	2,663		$	41,210
	Property and equipment, net		2,074			—			2,074
	Revenues		4,949			549			5,498
	Loss before taxes		(5,187	)		(35	)		(5,222	)

Business_Overview_and_Basis_of1

Business Overview and Basis of Presentation - Additional Information (Detail) (USD $)	3 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2013	Jun. 30, 2013	Jun. 30, 2015
	Subsidiary				Scenario Forecast [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'
Number of subsidiaries	2	'	'	'	'
Cash and cash equivalents	$5,445,475	$6,961,494	$14,643,050	$41,326,000	$41,000,000
Cash, cash equivalents and marketable securities	32,000,000	'	'	'	'
Utilized cash aggregated	$9,800,000	'	'	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Accounting Policies [Abstract]	'	'
Highly liquid investments, original maturity period	'3 months	'
Liability for uncertain tax positions	$0	'
Common stock equivalents excluded from the diluted per share calculation	7,461,763	7,708,560

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Financial Assets Recorded on Condensed Consolidated Balance Sheets (Detail) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	$27,806	$35,238
Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	1,264	367
U.S. Treasury Bonds [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	5,530	8,537
U.S. Government Sponsored Agencies [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	7,453	7,457
Corporate Debt Securities [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	13,559	18,877
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	27,806	35,238
Level 1 [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	1,264	367
Level 1 [Member] | U.S. Treasury Bonds [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	5,530	8,537
Level 1 [Member] | U.S. Government Sponsored Agencies [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	7,453	7,457
Level 1 [Member] | Corporate Debt Securities [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	13,559	18,877
Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Level 2 [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Level 2 [Member] | U.S. Treasury Bonds [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Level 2 [Member] | U.S. Government Sponsored Agencies [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Level 2 [Member] | Corporate Debt Securities [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Level 3 [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Level 3 [Member] | U.S. Treasury Bonds [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Level 3 [Member] | U.S. Government Sponsored Agencies [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Level 3 [Member] | Corporate Debt Securities [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Schedule of Options Weighted-Average Assumptions (Detail)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'
Expected dividend yield	0.00%	0.00%
Expected option term (years)	'5 years 26 days	'5 years 2 months 12 days
Expected stock price volatility	61.00%	67.00%
Risk-free interest rate	1.60%	'
Risk-free interest rate, minimum	'	1.56%
Risk-free interest rate, maximum	'	1.74%

Marketable_Securities_Componen

Marketable Securities - Components of Marketable Securities (Detail) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	$26,546	$34,871
Gross Unrealized Gain	6	13
Gross Unrealized (Loss)	-10	-13
Fair Value	26,542	34,871
U.S. Treasury Bonds [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	5,529	8,537
Gross Unrealized Gain	1	1
Gross Unrealized (Loss)	'	-1
Fair Value	5,530	8,537
U.S. Government Sponsored Agencies [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	7,453	7,458
Gross Unrealized Gain	'	'
Gross Unrealized (Loss)	'	-1
Fair Value	7,453	7,457
Corporate Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	13,564	18,876
Gross Unrealized Gain	5	12
Gross Unrealized (Loss)	-10	-11
Fair Value	$13,559	$18,877

Marketable_Securities_Maturiti

Marketable Securities - Maturities of Debt Securities Classified as Available-for-Sale (Detail) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Investments, Debt and Equity Securities [Abstract]	'	'
Fair Value, Due within one year	$24,943	$25,336
Fair Value, Due after one year through five years	1,599	9,535
Fair Value	26,542	34,871
Net Carrying Amount, Due within one year	25,027	25,449
Net Carrying Amount, Due after one year through five years	1,610	9,603
Net Carrying Amount	$26,637	$35,052

Marketable_Securities_Addition

Marketable Securities - Additional Information (Detail) (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Investments, Debt and Equity Securities [Abstract]	'	'
Proceeds from sales/maturities of marketable securities	$8,336,478	'

Stockholders_Equity_Components

Stockholders' Equity - Components of Accumulated Other Comprehensive Income (Detail) (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'
Beginning, Balance	$261,837	$161,830
Other comprehensive income (loss) before reclassifications	-175,367	67,407
Amounts reclassified from accumulated other comprehensive income	-7,215	'
Other comprehensive (loss) income	-182,582	67,407
Ending, Balance	79,255	229,237
Currency Translation Adjustments [Member]	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'
Beginning, Balance	261,924	161,830
Other comprehensive income (loss) before reclassifications	-178,130	72,367
Amounts reclassified from accumulated other comprehensive income	'	'
Other comprehensive (loss) income	-178,130	72,367
Ending, Balance	83,794	234,197
Net Unrealized (Losses) Gains on Available-for-Sale Securities [Member]	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'
Beginning, Balance	-87	'
Other comprehensive income (loss) before reclassifications	2,763	-4,960
Amounts reclassified from accumulated other comprehensive income	-7,215	'
Other comprehensive (loss) income	-4,452	-4,960
Ending, Balance	($4,539)	($4,960)

Stockholders_Equity_Components1

Stockholders' Equity - Components of Accumulated Other Comprehensive Income (Parenthetical) (Detail) (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'
Reclassified from accumulated other comprehensive income	$25,072	$6,211
Reclassification out of Accumulated Other Comprehensive Income [Member]	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'
Reclassified from accumulated other comprehensive income	$7,215	$0

Stock_Incentive_Plan_Additiona

Stock Incentive Plan - Additional Information (Detail) (USD $)

3 Months Ended

3 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Aug. 14, 2014

Sep. 30, 2014

Sep. 30, 2013

Restricted Stock [Member]

Restricted Stock [Member]

Stock Option [Member]

Performance Units [Member]

Performance Units [Member]

Performance Units [Member]

Employees, Executive Officers and Non-Employee Board Members [Member]

Employees, Executive Officers and Non-Employee Board Members [Member]

Board Members [Member]

Executive Officers [Member]

Executive Officers [Member]

Executive Officers [Member]

Executive Officers [Member]

Maximum [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Performance Units vesting period

'4 years

'

'4 years

'

'

'

'

'5 years

'

'

'

'

'

'

'

Contractual terms of stock option

'7 years

'

'

'

'

'

'

'

'

'

'7 year

'

'

'

'

Common stock reserved for possible future issuance upon exercise of stock options

9,857,606

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options available for future grants

6,461,763

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Performance Units available for grant

3,395,843

'

'

'

'

389,864

'

'

'

'

'

'

'

'

'

Weighted average fair value at the date of grant for options granted

$1.75

$3.07

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-vested options outstanding

2,036,919

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation costs related to non-vested share-based compensation

$3,000,000

'

'

'

'

$900,000

'

'

'

'

'

$1,800,000

'

'

'

Stock-based compensation expense related stock options

'

'

'

'

'

'

'

'

600,000

400,000

'

'

'

200,000

100,000

Weighted-average period recognized

'3 years

'

'

'

'

'2 years 4 months 24 days

'

'

'

'

'

'2 years 9 months 18 days

'

'

'

Value of shares to be granted for non-employee Board members

'

'

45,000

'

45,000

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

'

'

45,000

55,000

'

'

'

'

'

'

'

'

'

'

'

Restricted stock units

'

'

'

'

'

'

'

'

'

'

'

'

226,657

'

'

Restricted stock units, market price

'

'

'

'

'

'

'

'

'

'

'

'

$3.32

'

'

Stock-based compensation

'

'

'

'

'

$32,000

$200,000

'

'

'

'

'

'

'

'

Stock_Incentive_Plan_Summary_o

Stock Incentive Plan - Summary of Options (Detail) (USD $)	3 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Number of Shares, Options outstanding, beginning of year	5,308,617
Number of Shares, Options granted	488,719
Number of Shares, Options cancelled or forfeited	-280,500
Number of Shares, Options outstanding, end of year	5,516,836
Number of Shares, Options exercisable, end of year	4,027,480
Weighted Average Exercise Price, Options outstanding, beginning of year	$3.41
Weighted Average Exercise Price, Options granted	$3.32
Weighted Average Exercise Price, Options cancelled or forfeited	$4.40
Weighted Average Exercise Price, Options outstanding, end of year	$3.35
Weighted Average Exercise Price, Options exercisable, end of year	$3.16
Weighted Average Remaining Contractual Life of outstanding stock options	'3 years 8 months 1 day
Weighted Average Remaining Contractual Life of exercisable stock options	'2 years 9 months 4 days
Aggregate Intrinsic Value of outstanding stock options	$3,445,495
Aggregate Intrinsic Value of exercisable stock options	$3,142,578

Stock_Incentive_Plan_NonVested

Stock Incentive Plan - Non-Vested Restricted and Performance Stock Units (Detail)	3 Months Ended
	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Non-vested at July 1, 2014	788,364
Vested	-397,364
Exercised	-70,094
Non-vested at September 30, 2014	547,563
Restricted Stock [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Granted	226,657

Geographic_Segments_Financial_

Geographic Segments - Financial Information Based on Geographic Location of Facilities (Detail) (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014
Segment Reporting Information [Line Items]	'	'	'
Total assets	$37,815,905	$41,210,000	$47,486,482
Property and equipment, net	2,086,408	2,074,000	1,895,475
Revenues	1,071,998	5,497,821	'
(Loss) income before taxes	-12,430,799	-5,221,682	'
United States [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Total assets	35,017,000	38,547,000	'
Property and equipment, net	2,086,000	2,074,000	'
Revenues	368,000	4,949,000	'
(Loss) income before taxes	-12,455,000	-5,187,000	'
Europe [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Total assets	2,799,000	2,663,000	'
Property and equipment, net	'	'	'
Revenues	704,000	549,000	'
(Loss) income before taxes	$24,000	($35,000)	'

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Related Party Transaction [Line Items]	'	'
Research related activities charges	$9,392,017	$7,514,094
Compensation received for services	21,000	20,000
Center for Molecular Medicine and Immunology [Member]	'	'
Related Party Transaction [Line Items]	'	'
Area of subleased property	1,000	'
Subleases cost	30,000	'
Legal expenses incurred by the company	10,000	5,000
Research related activities charges	$0	$0

License_and_Collaboration_Agre1

License and Collaboration Agreements - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended			3 Months Ended	0 Months Ended	3 Months Ended
	Dec. 27, 2011	Jan. 31, 2012	Sep. 30, 2014	Sep. 30, 2013	Dec. 27, 2011	Sep. 30, 2014	9-May-06	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Mar. 06, 2014
						Nycomed Agreement [Member]	UCB Agreement [Member]	UCB Agreement [Member]	UCB Agreement [Member]	The Bayer Group [Member]	The Bayer Group [Member]
									Maximum [Member]
Guarantor Obligations [Line Items]	'	'	'	'	'	'	'	'	'	'	'
License agreement date	'	'	'	'	'	11-Jul-08	'	9-May-06	'	'	'
Acquisition completion date	'	'	'	'	'	30-Sep-11	'	'	'	'	'
Non-refundable cash payment received	'	$30,000,000	'	'	'	'	$38,000,000	'	'	'	'
Amendment agreement date	'	'	'	'	'	'	27-Dec-11	'	'	'	'
Duration of warrant issued	'5 years	'	'	'	'	'	'	'	'	'	'
Number of shares under five year warrant	'	'	'	'	1,000,000	'	'	'	'	'	'
Shares to be purchased under warrant, par value	'	'	'	'	$0.01	'	'	'	'	'	'
Shares to be purchased under warrant, exercise price	'	'	'	'	$8	'	'	'	'	'	'
Cash payment receivable	'	'	'	'	'	'	'	'	145,000,000	'	'
Equity investments receivable	'	'	'	'	'	'	'	'	20,000,000	'	'
Achievement of specified product sales milestones	'	'	'	'	'	'	'	'	260,000,000	'	'
Product royalties term, description	'	'	'	'	'	'	'	'The Company is also entitled to product royalties ranging from a mid-teen to mid-twenty percentage of aggregate annual net sales under the UCB Agreement and Amendment Agreement during the product royalty term.	'	'	'
Termination period	'	'	'	'	'	'	'	'60 days	'	'	'
Additional amounts payable after effective date of termination	'	'	'	'	'	'	'	0	'	'	'
Collaboration agreement date	'	'	'	'	'	'	'	'	'	'2013-01	'
Collaboration agreement amendment date	'	'	'	'	'	'	'	'	'	2-Aug-13	'
License fee revenue	'	'	'	'	'	'	'	'	'	4,600,000	'
Cost of license fee and other revenues	'	'	'	$1,189,170	'	'	'	'	'	$1,200,000	'
Percentage of shares voluntary takeover	'	'	'	'	'	'	'	'	'	'	98.20%

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Guarantor Obligations [Line Items]	'	'
Number of shareholder derivative complaints	2	'
Goldenberg Agreement [Member]	'	'
Guarantor Obligations [Line Items]	'	'
Minimum additional incentive compensation, royalty payments and disposition of undeveloped assets	$37,500	'
Additional incentive compensation paid	0	0
Nycomed Agreement [Member]	'	'
Guarantor Obligations [Line Items]	'	'
Agreement termination date	9-Oct-13	'
Employment Agreement [Member] | Goldenberg Agreement [Member]	'	'
Guarantor Obligations [Line Items]	'	'
Annual base salary	500,000	'
Percentage of increase in annual base salary for next fiscal year	3.50%	'
Percentage of annual bonus target	50.00%	'
Agreement termination date	1-Jul-16	'
Agreement date	1-Jul-11	'
Employment Agreement [Member] | Goldenberg Agreement [Member] | Scenario Forecast [Member]	'	'
Guarantor Obligations [Line Items]	'	'
Annual base salary	600,000	'
Employment Agreement [Member] | Goldenberg Agreement [Member] | Minimum [Member]	'	'
Guarantor Obligations [Line Items]	'	'
Percentage of potential payout target	0.00%	'
Employment Agreement [Member] | Goldenberg Agreement [Member] | Maximum [Member]	'	'
Guarantor Obligations [Line Items]	'	'
Percentage of potential payout target	150.00%	'
Employment Agreement [Member] | Sullivan Agreement [Member]	'	'
Guarantor Obligations [Line Items]	'	'
Annual base salary	$600,000	'
Percentage of increase in annual base salary for next fiscal year	3.50%	'
Percentage of annual bonus target	50.00%	'
Agreement termination date	1-Jul-17	'
Agreement date	1-Jul-14	'
Employment Agreement [Member] | Sullivan Agreement [Member] | Minimum [Member]	'	'
Guarantor Obligations [Line Items]	'	'
Percentage of potential payout target	0.00%	'
Employment Agreement [Member] | Sullivan Agreement [Member] | Maximum [Member]	'	'
Guarantor Obligations [Line Items]	'	'
Percentage of potential payout target	150.00%	'
First Lawsuit [Member]	'	'
Guarantor Obligations [Line Items]	'	'
Lawsuit filing date	'March 24, 2014	'
Second Lawsuit [Member]	'	'
Guarantor Obligations [Line Items]	'	'
Lawsuit filing date	'April 18, 2014	'
Class Action Lawsuits [Member]	'	'
Guarantor Obligations [Line Items]	'	'
Lawsuit filing date	'2014-02-27	'

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Subsequent Event [Line Items]	'
Shelf registration process, description	'Company may issue, in one or more offerings, any combination of common stock, preferred stock senior or subordinated debt securities, warrants, or units, up to a total dollar amount of $130.0 million.
Scenario Forecast [Member] | Maximum [Member]	'
Subsequent Event [Line Items]	'
Shelf registration process, securities total dollar amount	130